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Abstract: An association has been shown between plasma renin activity (PRA) and the risk of 
cardiovascular disease. There is also evidence that angiotensin II exerts detrimental effects on 
progression and instabilization of atherosclerotic plaque. The renin-angiotensin system (RAS) 
can be inhibited through inhibition of angiotensin I (Ang I) generation from angiotensinogen 
by direct renin inhibitors, inhibition of angiotensin II (Ang II) generation from angiotensin I 
by angiotensin-converting enzyme inhibitors and ﬁ  nally by direct inhibition of the action of 
Ang II receptor level. Aliskiren, the ﬁ  rst direct renin inhibitor to reach the market, is a low-
molecular-weight, orally active, hydrophilic nonpeptide. Aliskiren blocks Ang I generation, while 
plasma renin concentration increases because the drugs blocks the negative feed-back exerted 
by Ang II on renin synthesis. Because of its long pharmacological half-life, aliskiren is suitable 
for once-daily administration. Its through-to-peak ratio approximates 98% for the 300 mg/day 
dose. Because of its mechanism of action, aliskiren might offer the additional opportunity to 
inhibit progression of atherosclerosis at tissue level. Hypertension is an approved indication for 
this drug, which is also promising for the treatment of heart failure. The efﬁ  cacy of this drug in 
reducing major clinical events is being tested in large ongoing clinical trials.
Keywords: plasma renin activity, renin angiotensin system, aliskiren, angiotensinogen, renin, 
hypertension, heart failure, diabetes
A link between plasma renin activity (PRA) and risk of cardiovascular disease has been 
demonstrated in several (Brunner et al 1972; Alderman et al 1991, 1997; Campbell 
et al 2005), but not all (Doyle et al 1973; Meade et al 1993) epidemiological studies. 
Such a link is also supported by many experimental and clinical studies which provided 
convincing evidence that the renin-angiotensin system (RAS) is capable of stimulating 
atherosclerosis by triggering basic reactions which ultimately lead to growth, instability, 
and rupture of atherosclerotic plaques and facilitation of thrombosis (Schmidt-Ott et al 
2000; Jacoby and Rader 2003) (Figure 1).
Mechanisms of pharmacological inhibition
of the RAS
The pharmacological inhibition of the RAS can be achieved through 3 different basic 
mechanisms (Skeggs et al 1957) (Figure 2):
1)  Inhibition of angiotensin I (Ang I) generation from angiotensinogen. This can 
be achieved by direct inhibition of renin, an aspartyl protease that releases the 
decapeptide Ang I from the α-2-globulin angiotensinogen.Vascular Health and Risk Management 2008:4(5) 972
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2)  Inhibition of angiotensin II (Ang II) generation from 
angiotensin I. This can be achieved through inhibition 
of angiotensin-converting enzyme (ACE), a zinc-
dependent protease that generates the octapeptide 
hormone angiotensin II (Ang II) by cleaving 2 amino 
acids (histidine and leucine) from Ang I. ACE is highly 
expressed in the kidney and pulmonary endothelium.
3) Inhibition of the action of Ang II at the level of its 
receptor(s).
In a landmark paper published more than 50 years 
ago, Skeggs et at (1957), ﬁ  rst suggested that inhibition of 
Ang I generation from angiotensinogen was the therapeutic 
approach “most likely to succeed” because renin is the initial 
and rate-limiting step of the RAS.
Unfortunately, at variance with ACE inhibitors and Ang II 
receptor blockers, direct inhibitors of renin had to wait many 
years before becoming available for clinical use. Important 
technical problems in identifying and developing suitable 
agents sharing an elevated afﬁ  nity for the renin’s active site 
and sufﬁ  cient bioavailability to allow oral administration 
precluded their clinical use for a long time.
Angiotensinogen, prorenin,
and renin
Angiotensinogen: the ﬁ  rst substrate
Human angiotensinogen, the substrate on which renin 
exerts its activity, is a 118-amino-acid-long polypeptide 
(an α-2-globulin) that is generated mainly in the liver. Other 
species have angiotensinogen of different sizes. Plasma 
angiotensinogen levels are increased by Ang II, plasma 
corticosteroid, estrogen, and thyroid hormones.
How does Ang I origin from angiotensinogen? 
A 7-amino acid residue of angiotensinogen is accommodated 
into a deep cleft of renin. This causes hydrolysis of the 
Leu10-Val11 bond and generation of the decapeptide 
fragment Ang I (James and Sielecki 1985). Ang I gives origin 
to the octapeptide hormone Ang II through the action of ACE, 
a zinc-dependent protease present in several tissues, which 
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cleaves 2 amino acids from Ang I, thus releasing Ang II. 
Ang I can also be transformed into Ang(1,9) by ACE2, a 
carboxypeptidase that also mediates the transformation of 
Ang II into Ang(1,7) (Donoghue et al 2000). ACE2 has a 
greater afﬁ  nity for Ang II than it has for Ang I. The effect 
of ACE2 on Ang II tends to counterbalance the adverse 
effects of Ang II.
Ang II binds to 2 main receptors, Ang II type 1 (AT1) 
and Ang II type II (AT2). Ang II can also be hydrolyzed 
by speciﬁ  c proteases to generate other peptides including 
Ang (1–7), which binds to AT3 receptors, and Ang IV, which 
binds to AT4 receptors (Turner 2003).
Structure and activity of renin
Renin, a 340-amino acid protease polypeptide, is a member 
of the aspartyl protease superfamily, which includes 
pepsin, cathepsin D, and chymosin (Wood et al 1987). 
Renin results from a molecular change of its precursor, 
prorenin. Structurally, renin consists of 2 lobes with a long 
and deep cleft between them (Sielecki et al 1989; Rahuel 
et al 2000).
The cleft, the active site of renin, accommodates a 
7-amino acid residue of angiotensinogen. Two aspartic 
acid residues (Asp32 and Asp215 in human renin), each 
located in a single lobe of renin, control the ﬁ  rst and rate-
limiting step of the RAS by catalyzing the hydrolysis of the 
Leu10–Val11 peptide bond of angiotensinogen and releasing 
the decapeptide Ang I (James and Sielecki 1985) (Fig. 3).
An important point to note is that, at variance with other 
aspartic proteases such as pepsin or cathepsin D, renin is 
fully speciﬁ  c for angiotensinogen.
Structure and activity of prorenin
Prorenin, the inactive precursor of renin, is a pre-hormone 
synthesized in adrenals, retina, ovaries, and testis (Danser 
et al 1989; Sealey et al 1988; Itskovitz et al 1992; Clausmeyer 
et al 1999). The extra renal sites of synthesis explain why 
nephrectomized subjects show circulating prorenin levels of 
about 50% of those in normal subjects. Synthesis in ovaries 
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explains why prorenin levels are high in pregnancy (Derkx 
et al 1987; Itskovitz et al 1987).
Interestingly, Ang I and Ang II in nephrectomized 
subjects are extremely low despite prorenin levels about 
half the normal (Derkx and Schalekamp 1988). This ﬁ  nding 
is consistent with a very low intrinsic enzymatic activity 
of prorenin (3% of fully activated renin). In diabetic 
subjects with prolipherative retinopathy, levels of prorenin 
in the vitreous are about 100-times higher than in plasma 
(Wilkinson-Berka 2004).
Administration of prorenin does not cause any rise in 
blood pressure in experimental animals. It is believed that the 
absence of enzymatic activity of prorenin is due to a 43-amino 
acid N-terminal propeptide which covers the enzymatic cleft, 
thereby denying the access of angiotensinogen to the active 
site of renin (Figure 3).
Transformation of inactive prorenin into the active form 
renin is a fundamental reaction that may be irreversible 
(proteolytic) or reversible (nonproteolytic). The irreversible 
proteolytic activation occurs in the juxtaglomerular cells of 
kidney (Reudelhuber et al 1994). It consists of the removal 
of the 43-amino acid propeptide. It seems to be operated by 
various enzymes including proconvertase 1, cathepsin B, 
trypsin, plasmin, and kallikrein.
The reversible nonproteolytic activation of prorenin 
consists of a sort of unfolding of the propeptide from the 
enzymatic cleft (Danser et al 2008) (Figure 3). Initially, the 
43-amino acid propeptide moves out of the enzymatic cleft 
without detaching from the main molecule. Subsequently, 
the molecule assumes its enzymatically active conforma-
tion. Low pH (acid activation) and cold (cryoactivation) 
are potent stimulants of nonproteolytic activation of 
prorenin.
When prorenin has been nonproteolytically activated, 
it is fully active and can be recognized by monoclonal 
antibodies that are speciﬁ  c for the active site. It is impor-
tant to note that these antibodies may recognize prorenin 
even after incubation with a renin inhibitor. This may 
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lead to some overestimation of the degree of reactive 
prorenin synthesis during direct renin inhibition (Menard 
et al 2006).
Circulating renin and prorenin
Circulating levels of renin are 1 pmol/L in humans and 
levels of prorenin are about 10-fold higher (Danser et al 
1998). However, circulating levels of prorenin and renin 
tend to be related. Under physiological conditions, less 
than 2% of prorenin is in the active conformation. Acute 
stimuli may cause a sudden increase in the release of 
active renin from the juxtaglomerular apparatus without 
any immediate rise in the prorenin levels, while chronic 
stimuli may lead to a rise in both renin and prorenin, with 
a higher rate of conversion of inactive prorenin into active 
renin (Danser et al 2008). Prorenin has a low intrinsic 
activity on angiotensinogen which is 3% than fully 
activated renin.
Stimulation of AT1 receptors by Ang II inhibits renin 
release. In contrast, inhibition of RAS at any level increases 
renin release by attenuating the negative feedback effect by 
Ang II (Figure 4).
In patients with diabetes mellitus, as well as during 
pregnancy, there is usually a rise in prorenin levels with 
an increased prorenin/renin ratio. In patients with dia-
betes, prorenin levels may even predict the occurrence 
of subsequent nephropathy (Luetscher et al 1985; Price 
et al 1999).
Renin and prorenin receptors
Most of Ang II generated in the heart and vessels 
derives from the active renin generated in the kidney and 
removed from the circulation at tissue level. However, recent 
data suggest that circulating prorenin may be sequestrated 
from blood through speciﬁ  c receptors and converted into 
active renin in tissues. Several receptors for prorenin and 
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renin have been described in different tissues including 
kidney (mesangium and collecting tubules), brain, vascular 
smooth muscle, and cardiac myocites (Nguyen et al 2002).
Because both renin and prorenin competitively bind to 
these receptors, the term ‘(pro)renin’ receptors has been 
introduced. Binding afﬁ  nity of these receptors is higher for 
prorenin than for renin (Nabi et al 2006).
When circulating prorenin binds to (pro)renin receptors it 
undergoes, to effect binding, some conformational changes, 
without cleaving of the 43-amino acid segment, with 
enlargement of the cleft and consequent enzymatic activation 
(Figure 3). This phenomenon of nonproteolytic activation 
occurs at the surface of the cell (ie, without internalization 
of prorenin). It could lead to local generation of Ang I from 
circulating angiotensinogen. Because synthesis of Ang I 
occurs in close proximity to tissue ACE, this may lead to 
immediate synthesis of Ang II. When circulating renin binds 
to these receptors, its enzymatic activity on angiotensinogen 
increases, with enhanced local generation of Ang I (Bader 
and Ganten 2008).
After binding to (pro)renin receptors, renin and prorenin 
are not internalized into the cell. In contrast, renin and 
prorenin bound to the mannose-6-phosphate receptor 
(M6P-R), a clearance receptor, may be internalized (van 
Kesteren et al 1997).
An important question to address is whether the binding 
capacity of (pro)renin receptors for circulation renin and 
prorenin is enough for the picomolar concentrations of renin 
and prorenin that occur in vivo. In fact, experimental studies 
of (pro)renin receptors often used very high concentrations 
of renin and prorenin, much in excess of those normally 
occurring in vivo.
Localization of renin and prorenin in the heart is particularly 
attractive (Bader and Ganten 2008). Both renin and prorenin 
bind to (pro)renin receptors located on the membranes of endo-
thelial cells, vascular smooth cells and myocites. In the same 
time, renin and prorenin diffuse slowly into the interstitial space, 
reaching interstitial concentrations similar to those in plasma.
Once sequestrated into tissues, circulating renin and 
prorenin not only enhance local Ang II synthesis, but also 
directly trigger Ang-II independent reactions which might be 
potentially active on the development of atherosclerotic plaque 
(Nguyen 2006; Oliver 2006). These reactions include:
a)  Activation of intracellular kinases.
b)  Stimulation of DNA synthesis.
c)  Increased release of plasminogen activator inhibitor 
(PAI-1) and transforming growth factor (TGF)-β 
(Ichihara et al 2006; Nguyen and Danser 2006).
It is important to note that these reactions may occur in 
the absence of Ang II action, as suggested by the inability of 
ACE inhibitors or angiotensin II receptor blockers to block 
these effects (Huang et al 2006).
It will be very important to clarify whether speciﬁ  c renin 
inhibitors can inhibit these Ang-II independent reactions trig-
gered by activated renin at the tissue level and whether such 
an effect may lead to beneﬁ  cial effects potentially speciﬁ  c 
for this class of drugs.
Aliskiren
Aliskiren, a 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-
2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-
(4-methoxy-3-[3-methoxypropoxy-]phenyl)-octanamide, 
is the only orally active renin inhibitor that successfully 
progressed to phase III trials and extensive clinical use.
Chemical properties
Aliskiren is a low-molecular-weight hydrophilic nonpeptide 
which exerts a potent and speciﬁ  c competitive inhibition on 
renin in primates (Wood et al 2003) (Figure 5). The very high 
speciﬁ  city for renin (10,000-fold higher afﬁ  nity for renin 
than for other aspartic peptidases) makes aliskiren unlikely 
to cause adverse effects potentially related to inhibition of 
other peptidases.
Because renin is a water-soluble protein that can be 
studied with crystallographic analysis (Rahuel et al 2000), 
the opportunity arose to examine systematically the crystals 
of renin bond to renin inhibitors. Consequently, the devel-
opment of aliskiren was the result of successive steps of 
molecular modeling on earlier peptide-like renin inhibitors 
(Wood et al 2003). These steps were aimed to improve the 
afﬁ  nity for the active enzymatic subpocket of renin and to 
prolong the duration of action of the drug.
The high potency of aliskiren is reﬂ  ected by the ﬁ  nding 
that the concentration at which this drug can inhibit 50% of 
renin activity is only 0.6 nmol/L (Wood et al 2003).
After oral administration in healthy volunteers, the 
plasma concentration of aliskiren increases in a dose-
dependent fashion with peak concentrations after 3–6 hours, 
average plasma half-life of 23.7 hours (range 20–45 hours), 
oral bioavailability of about 5% (for 95% it is excreted 
unchanged in feces), and plasma steady-state levels after 
5–8 days of treatment (Waldmeier et al 2007).
Of particular note, aliskiren is not subject to metabolism 
by the cytochrome P450 and does not interact with metabo-
lism of warfarin and a number of other compounds including 
lovastatin, atorvastatin, digoxin, atenolol, celecoxib, Vascular Health and Risk Management 2008:4(5) 977
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metformine, ramipril, hydrochlorothiazide, and cimetidine 
(Dieterle et al 2004, 2005).
Pharmacodynamic properties
Since important molecular differences exist in the structure 
of renin and angiotensinogen between different species, 
inhibitors of human renin are speciﬁ  c for primates and 
ineffective or scarcely effective in nonprimates. In sodium-
depleted marmosets (which are primates), aliskiren at 
3 mg/kg daily completely inhibited PRA for 24 hours (Wood 
et al 2005). The effect of aliskiren on blood pressure (BP) 
was dose-dependent, with a persistence of the effect for 
24 hours.
In marmosets, aliskiren was more effective than other 
renin inhibitors (zanchiren and remikiren) in lowering BP.
In order to obviate the speciﬁ  city of aliskiren for primate 
renin, double transgenic rats were developed with human 
genes for renin and angiotensinogen (Ganten et al 1992; 
Fukamizu et al 1993). In these rats, low and high doses of 
aliskiren and valsartan were compared with placebo to inves-
tigate their effects on left ventricular hypertrophy, creatinine, 
albuminuria, and mortality. In summary, both doses of 
aliskiren but only the higher dose of valsartan decreased all of 
the above end-points compared with placebo. After 3 weeks, 
74% of rats treated with the low valsartan dose, but 100% of 
rats treated with the high valsartan dose and both aliskiren 
doses survived, compared with none of the the untreated rats 
(Pilz et al 2005).
A group of healthy normotensive volunteers put on a 
constant sodium diet (100 mmol/day) received aliskiren 
(40–80 mg/day or 160–640 mg/day), enalapril (20 mg/day) 
or placebo. Aliskiren decreased PRA, Ang I, and Ang II 
in a dose-dependent fashion. In comparison with placebo, 
the higher dose of aliskiren reduced Ang II by 80% and 
increased plasma renin concentration by more than 10 times. 
The reduction in Ang II was comparable between enalapril 
20 mg/day and aliskiren 160 mg/day. Neither BP nor heart 
rate were affected by aliskiren and enalapril in these normo-
tensive subjects (Nussberger et al 2002).
In a within-subject study, 12 sodium-depleted normo-
tensive subjects were randomly given placebo, aliskiren 
300 mg/day, valsartan 160 mg/day, and the combination 
of aliskiren and valsartan (150 mg/day +80 mg/day). As 
expected, aliskiren alone decreased PRA while valsartan 
alone increased PRA, Ang I and Ang II. The combination 
of aliskiren and valsartan completely eliminated the rise in 
PRA elicited by valsartan (Azizi et al 2004).
Studies in hypertension
In placebo-controlled studies in hypertensive subjects 
(Kushiro et al 2006; Mitchell 2006; Jordan et al 2007; Oh 
et al 2007; Oparil et al 2007; Pool et al 2007; Villamil 
et al 2007), aliskiren produced a dose-related BP reduc-
tion at doses between 75 and 300 mg/day. There was little 
or no effect below 75 mg, and no additional BP-lowering 
effect above 300 mg. Most of the effect on BP occurred 
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after 2 weeks, and a near maximal effect was noted 
after 4 weeks. A pooled analysis by Dahlof et al (2007) 
showed mean reductions in systolic BP of 5.9, 12.5, and 
15.2 mmHg with placebo, aliskiren 150 mg/day, and 
aliskiren 300 mg/day. The corresponding mean reduc-
tions in diastolic BP were 6.2, 10.1, and 11.8 mmHg, 
respectively. Interestingly, the antihypertensive response 
to aliskiren was comparable in men and women, and also 
between subjects of different age.
The long pharmacological half-life of aliskiren makes this 
drug very suitable for once-daily use. In studies with 24-hour 
ambulatory BP monitoring (Stanton et al 2003; Gradman et al 
2005b), aliskiren effectively reduced BP for 24 hours with a 
through-to-peak ratio of  98% for the daily 300 mg/day dose, 
and 64% for the 150 mg/day dose.
In a double-blind study (Oparil et al 2007), 1797 hyper-
tensive patients were randomly assigned to receive aliskiren 
150 mg/day alone, valsartan 160 mg/day alone, a combi-
nation of aliskiren and valsartan, or placebo for 4 weeks. 
Then the dose in each arm was doubled to the maximum 
recommended dose (300 and 320 mg/day, respectively) for 
another 4 weeks. At 8 weeks, the combination of aliskiren 
and valsartan lowered diastolic BP from baseline by 12.2 mm 
Hg, more than monotherapy with aliskiren (−9.0 mmHg), 
valsartan (−9.7 mmHg), or placebo (−4.1 mmHg). Adverse 
events and laboratory abnormalities were similar in the 
four groups. This study suggests that the combination of 
aliskiren and valsartan at the maximum recommended doses 
provides greater reductions in BP than monotherapy with 
either agent, with a tolerability proﬁ  le not dissimilar from 
that of monotherapies. To explain these data, it should be 
considered that the RAS is a self-regulating system which is 
controlled by a negative feedback inhibition. The stimulation 
of the AT1 receptors by Ang II immediately suppresses the 
release of renin from the juxtaglomerular cells. Angiotensin 
receptor blockade stimulates renin production by inhibiting 
the action of Ang II on AT1 receptors. Such compensatory 
activation of the RAS may limit the efﬁ  cacy of AT1 receptor 
blockers and therefore the simultaneous administration of a 
direct renin inhibitor such as aliskiren may produce a better 
antihypertensive response.
Aliskiren has been compared with several antihypertensive 
drugs including hydrochlorothiazide, ramipril, lisinopril, 
losartan, irbesartan, and valsartan (Stanton et al 2003; 
Gradman et al 2005a; Uresin et al 2006; Andersen et al 
2007; Oparil et al 2007; Strasser et al 2007; Villamil et al 
2007). In general, the antihypertensive effect of aliskiren was 
similar to that of active comparators. As expected, no rise 
in PRA occurred with aliskiren, at variance with the active 
comparators, in the trials which it was assessed.
As a results of these studies, the US Food and Drug 
Administration approved the use of aliskiren in hypertension 
up to a maximal dose of 300 mg/day.
Trials on intermediate end-points
Some important phase-III clinical trials have just been 
completed. These trials tested the effect of aliskiren on markers 
of organ damage in approximately 300–500 patients.
a)  The Aliskiren in Left-Ventricular Hypertrophy trial 
(ALLAY, registration number [http://clinicaltrial.gov] 
NCT00219141) (Solomon 2008) was a randomized 
between-patient comparison of aliskiren, losartan, and 
their combination in hypertensive subjects with left-
ventricular hypertrophy. The primary endpoint consisted 
in the changes in left-ventricular mass as assessed by 
magnetic resonance imaging. After 34 weeks of treat-
ment, left ventricular mass decreased slightly more with 
aliskiren + losartan (−6.4%) than it did with aliskiren 
alone (−5.4%) or losartan alone (−4.7%), although the 
differences between the three groups were not statistically 
signiﬁ  cant.
b)  The Aliskiren Observation of Heart Failure Treatment 
trial (ALOFT, NCT00219011) (McMurray et al 2008) 
was a randomized between-patient comparison of 
aliskiren 150 mg/day and placebo (on top of standard 
treatment including ACE inhibitors or angiotensin 
receptor blockers) in patients with heart failure. The 
primary endpoint consisted in the changes in the plasma 
concentration of N-terminal pro brain natriuretic peptide 
(NT-proBNP). Plasma levels of NT-proBNP rose by 
about 762 pg/mL with placebo and fell by 244 pg/mL 
with aliskiren (p = 0.0106). Aliskiren also reduced BNP 
and urinary (but not plasma) aldosterone. Thus, the 
ALOFT study demonstrated that the addition of aliskiren 
to an optimal therapy (which includes ACE inhibitors, 
angiotensin receptor blockers, and β-blockers) in patients 
with heart failure has favorable neurohumoral effects and 
is very well tolerated
c)  The Aliskiren in the Evaluation of  Proteinuria In Diabetes 
trial (AVOID, NCT00219206) (Parving et al 2008) was a 
randomized between-patient comparison between aliski-
ren (150 mg/day for 3 months and then 300 mg/day for 
other 3 months and placebo in addition to losartan 100 
mg/day in diabetic patients. Treatment of aliskiren reduced 
the mean urinary albumin-to-creatinine ratio by 20% 
(95% CI, 9–30; p  0.001). A reduction by 50% or more Vascular Health and Risk Management 2008:4(5) 979
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was noted in 24.7% of patients under aliskiren and 12.5% 
of patients under placebo (p  0.001). BP was 2/1 mmHg 
lower with aliskiren than with placebo and tolerability was 
the same in the two groups. The authors concluded that 
the renoprotective effects of aliskiren are independent of 
its antihypertensive effect in patients with hypertension, 
type 2 diabetes, and nephropathy who are being treated 
with an angiotensin receptor blocker (ARB).
The future of aliskiren
Aliskiren is the ﬁ  rst orally active direct renin inhibitor to 
successfully reach the market. Aliskiren blocks the generation 
of Ang I from angiotensinogen, the initial and rate-limiting step 
of the RAS, by inhibiting the active enzymatic site of renin. 
Not dissimilarly from other renin inhibitors, the BP-lowering 
affect of aliskiren is associated with a decreased, not increased, 
generation of Ang I. Conversely, plasma renin concentration 
markedly increases with aliskiren because the drug blocks the 
negative feedback exerted by Ang II on renin synthesis. Such 
an increase has been reported to be up to 34-fold (ie, much 
superior than that induced by ACE inhibitors or angiotensin 
receptor blockers). It will be important to clarify whether these 
very high levels of renin may exert biologically unwanted 
effects through stimulation of (pro)renin receptors.
It will be also important to verify whether the levels of 
Ang I and Ang II will remain suppressed during chronic 
therapy, in the absence of biologically relevant ACE-escape-
like phenomena. However, while concern about the escape 
phenomena usually focuses on the return of angiotensin II 
to pretreatment levels, the decreased PRA may be equally 
or more important since pre-treatment PRA is an indepen-
dent risk factor for myocardial infarction in hypertensive 
patients and for microvascular complications in diabetes 
(McInnes 2007). Although aliskiren increases plasma renin 
concentrations, PRA remains suppressed because cleavage 
of angiotensinogen is blocked.
The inhibition of Ang I generation is the unique feature 
that differentiates aliskiren not only from traditional 
antihypertensive drugs which activate the RAS (such as 
diuretics and calcium channel blockers), but also from ACE 
inhibitors and angiotensin receptor blockers. In addition, 
another promising feature of aliskiren is the potential for 
inhibiting renin and activated prorenin when they are bound 
to the (pro)renin receptors. On the other hand, aliskiren is 
unable to block the binding of prorenin and renin to (pro)renin 
receptors.
Because locally activated renin, as well as prorenin, 
may trigger reactions that can stimulate atherosclerosis, 
aliskiren might offer the additional opportunity of inhibiting 
progression of atherosclerosis at tissue level. Of course, these 
effects require further experimental and clinical testing.
The antihypertensive effect of aliskiren monotherapy 
seems to be comparable to that of ACE inhibitors, angiotensin 
receptor blockers, and other antihypertensive agents at 
equipotent doses. However, its antihypertensive efﬁ  cacy is 
enhanced by drugs that trigger a reactive increase in the PRA 
such as diuretics, ACE inhibitors and angiotensin receptor 
blockers (Stanton et al 2003; Gradman et al 2005a; Uresin 
et al 2006; Andersen et al 2007; Oparil et al 2007; Strasser 
et al 2007; Villamil et al 2007).
Aliskiren seems to be particularly indicated in patients 
who are intolerant to ACE inhibitors, as well as in those with 
elevated RAS activity, white subjects, and young people.
Aliskiren shares with the Ang II receptor blockers a 
placebo-like tolerability proﬁ  le (Weir et al 2006). In contrast 
to ACE inhibitors, aliskiren does not inhibit degradation 
of bradykinin. This might result in a lesser BP-lowering 
effect, outweighed by a better tolerability. In addition, the 
preferential hepatic elimination route of the drug and the lack 
of interference with several agents including warfarin and 
statins further enhance the tolerability proﬁ  le of the drug. The 
hepatic elimination route makes aliskiren safe in patients with 
renal failure. Similarly to ACE inhibitors and Ang II receptor 
blockers, pregnancy and bilateral renal artery stenosis are 
established contraindications to the use of the drug.
On the basis of the above considerations, hypertension 
and heart failure are the two conditions in which the effects 
aliskiren can be exploited most. However, the efﬁ  cacy of 
aliskiren in reducing major clinical events requires to be veri-
ﬁ  ed in large clinical trials. One of these trials, ALTITUDE 
(ALiskiren Trial In Type 2 diabetes Using cardio-renal 
Disease End-point), is ongoing. ALTITUDE is a random-
ized, placebo-controlled, double-blind study carried out in 
about 8600 patients with type 2 diabetes associated with 
persistent macroalbuminuria, persistent microalbuminuria, 
or a history of cardiovascular disease with reduced renal 
function. This is an event-driven study that will be concluded 
when 1628 patients will experience the primary end-point 
(composite of cardiovascular and renal events). Enrollment 
began in October 2007 and the study is expected to ﬁ  nish 
in 2012.
Two other studies are being planned. The ATMO-
SPHERE (Aliskiren Trial to Mediate Outcome Prevention 
in Heart FailuRE) will address heart failure patients similar 
to those included in ALOFT. Cardiovascular death and 
re-hospitalization for heart failure will be the components Vascular Health and Risk Management 2008:4(5) 980
Verdecchia et al
of the primary end-point. The APOLLO (Aliskiren in 
Prevention Of Later Life Outcomes) will address elderly 
subjects with normal BP (140/90 mmHg), no overt 
cardiovascular disease, and a high cardiovascular risk proﬁ  le, 
in order to test the efﬁ  cacy of the drug in reducing the risk 
of major cardiovascular end-points.
Furthermore, because aliskiren inhibits the initial and 
rate-limiting step of the RAS, it might become a reasonable 
therapeutic choice also in a broad number of clinical 
conditions, sharing an increased cardiovascular risk, where 
the inhibition of the RAS has been shown to be beneﬁ  cial. 
These conditions include stable coronary artery disease, 
cerebrovascular disease, diabetes, and peripheral arterial 
disease. A recent trial suggests that the ARB telmisartan 
is as good as (‘non inferior’ to) ramipril in these patients, 
although the tolerability proﬁ  le of telmisartan was superior 
to that of ramipril and the combination of the two drugs was 
not superior to the single ones (The 2008). Aliskiren has the 
potential to be useful in this wide spectrum of conditions. This 
would require the demonstration of non-inferiority versus 
other drugs inhibiting the RAS (ACE inhibitors, angiotensin 
receptor blockers) in properly designed clinical trials.
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